Adi Zuloff-Shani Ph.D.

About

Adi Zuloff-Shani, Ph.D., is the CEO of Clearmind Medicine [NASDAQ: CMND], a biotech company focused on the discovery and development of safe and novel psychedelic-derived therapeutics to treat alcohol use disorder as well as other pressing health challenges and addictions. The mentee of Raphael Mechoulam ("the godfather of cannabis research"), Dr. Zuloff-Shani works across scientific disciplines to bring new therapeutics through regulatory processes in the U.S., E.U., and Israel.

Dr. Zuloff-Shani holds a Bachelor of Science degree in Biology, a Master of Science degree in Immunology, and a Doctorate of Science degree in Immunology, all from Bar Ilan University. She is Chairman of Orsus Therapeutics Ltd. and serves on the advisory boards of Save Foods, Inc. [NASDAQ: SVFD]. Her executive experience in Research & Development in the biotech industry is combined with clinical work and knowledge of cell biology, innate immunity, tissue healing, and regeneration.

As CTO of SciSparc [NASDAQ: SPRC]—formerly Therapix Biosciences Ltd—Dr. Zuloff-Shani successfully brought products from bench to market for health challenges such as Tourette’s and obstructive sleep apnea and for CNS-related indications such as agitation in Alzheimer's, autism sectrum disorder, and pain. Prior to joining SciSparc, she served as Vice President of Development at Macrocure [NASDAQ: MCUR],

Recent Posts

Psychedelics Come of Age

A lot has changed since the 1960s. With FDA approvals for psychedelic-based treatments and new research, we're close to a major cultural shift towards psychedelics.

Why Psychedelics May Be the Future of Health Care

A Personal Perspective: Will psychedelic research completely change how we understand and treat mental health?

From Cannabinoids to Psychedelics

Personal Perspective: Keeping an open mind to the stigmatized fields of cannabinoids and psychedelics may deliver real solutions for health challenges.